Clinical Trial Update: SBRT + Atezolizumab + Bevacizumab in Resectable HCC [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial is evaluating the combination of SBRT (radiation therapy) with atezolizumab and bevacizumab in patients with resectable hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Resectable Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING